Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S7W-01755 · Session 7

Whether it plans to make teplizumab available through NHS Scotland and, if so, what is the anticipated timescale for its introduction.

Answered Asked by Sanne Dijkstra-Downie LD Lodged 16 Jul 2026

The question

To ask the Scottish Government whether it plans to make teplizumab available through NHS Scotland and, if so, what is the anticipated timescale for its introduction.

The answer

Answered by Angela Constance on 3 Aug 2026 · 18 days after it was lodged, on time

The Scottish Medicines Consortium (SMC) has received a full submission from the marketing authorisation holder, Sanofi, for teplizumab (Tzield®), to delay the onset of Stage 3 type 1 diabetes in adult and paediatric patients 8 years of age and older with Stage 2 type 1 diabetes.The SMC’s advice in relation to the routine use of teplizumab in the NHS in Scotland is expected to be published in 2027. The medicine product page on the SMC’s website will be updated with the advice, when published.

In the Official Report

No contribution in the Official Report cites S7W-01755 by reference.